Shanghai Huayi’s Diabetes Drug Enters Phase III
This article was originally published in PharmAsia News
Shanghai Huayi (Group) has started its Phase III trial for rhGLP-1, the first China-made incretin mimetic drug for treating type 2 diabetes. The clinical trial will be conducted in 14 major cities nationwide, covering nearly 20 hospitals with rich experience in endocrinology. With treatment effectiveness superior to traditional diabetes drugs, rhGLP-1 has received more than 10 domestic and overseas patents. To support registration and production of its new drugs, Huayi is stepping up the establishment of its pilot and industrial base such that phase one of the project will be completed next May. The firm expects rhGLP-1 to be launched within two years at a price far lower than similar imported products. (Click here for more - Chinese Language)
You may also be interested in...
Through a licensing-out deal with ORIC for its EGFR/HER2 exon-20 inhibitor, South Korea's Voronoi hopes to gain from its new partner's commercialization experience in NSCLC. The alliance hopes to build a potentially best-in-class presence in a competitive landscape.
An expert panel at the virtual HLTH conference discussed the role of robotics in improving health and wellness in the health continuum. See what Darla Hutton, vice president of US marketing and customer hospital analytics at Intuitive Surgical, said about the future of robotics.
With landmark advisory committee meetings coming up, we take a look back at some of the memorable panel meetings over the last 20 years.